(Q36191254)

12 August 2017

1 reference

title

Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next? (English)

1 reference

12 August 2017

1 reference

Fass R

1

1 reference

12 August 2017

Shapiro M

series ordinal

2

1 reference

12 August 2017

Dekel R

series ordinal

3

1 reference

12 August 2017

Sewell J

series ordinal

4

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

Alimentary Pharmacology & Therapeutics

12 August 2017

1 reference

12 August 2017

22

1 reference

12 August 2017

2

1 reference

12 August 2017

79-94

1 reference

"Refractory GERD": acid, nonacid, or not GERD?

12 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Effectiveness of proton pump inhibitors in nonerosive reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux--the "sensitive oesophagus"

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Functional heartburn: the stimulus, the pain, and the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Review article: is Helicobacter pylori status relevant in the management of GORD?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Gastroesophageal reflux disease--should we adopt a new conceptual framework?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Review article: the pathophysiology of gastro-oesophageal reflux disease - oesophageal manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Delayed gastric emptying in gastroesophageal reflux disease: reassessment with new methods and symptomatic correlations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Ambulatory esophageal pH monitoring using a wireless system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Feasibility and tolerability of transnasal/per-oral placement of the wireless pH capsule vs. traditional 24-h oesophageal pH monitoring--a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Outcomes of atypical symptoms attributed to gastroesophageal reflux treated by laparoscopic fundoplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02531.X

10.1111/J.1365-2036.2005.02531.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference